Delta Pathology Group, Llc - Mandeville

CLIA Laboratory Citation Details

2
Total Citations
16
Total Deficiencyies
7
Unique D-Tags
CMS Certification Number 19D1056551
Address 229 West Causeway Approach, Mandeville, LA, 70448
City Mandeville
State LA
Zip Code70448
Phone504 722-7684
Lab DirectorTHOMAS JR

Citation History (2 surveys)

Survey - December 10, 2019

Survey Type: Standard

Survey Event ID: 1LSM11

Deficiency Tags: D0000 D5209 D5609 D6093 D6103 D0000 D5209 D5609 D6093 D6103

Summary:

Summary Statement of Deficiencies D0000 A Certification Survey was performed on December 10, 2019 at Delta Pathology Group, LLC-Mandeville, CLIA ID # 19D1056551. The laboratory was found in compliance with 42 CFR 493 Requirements for Laboratories; however, standard level deficiencies were cited. D5209 PERSONNEL COMPETENCY ASSESSMENT POLICIES CFR(s): 493.1235 As specified in the personnel requirements in subpart M, the laboratory must establish and follow written policies and procedures to assess employee and, if applicable, consultant competency. This STANDARD is not met as evidenced by: Based on record review and interview with personnel, the laboratory failed to establish complete competency policies for testing personnel. Findings: 1. Review of the laboratory's policy and procedure manual revealed the laboratory did not include the following six (6) procedures as a minimal requirement for assessing the competency of all personnel performing laboratory testing: a) Direct observations of routine patient test performance, including patient preparation, if applicable, specimen handling, processing and testing. b) Monitoring the recording and reporting or test results. c) Review of intermediate test results or worksheets, quality control records, proficiency testing results, and preventative maintenance records. d) Direct observation of performance of instrument maintenance and function checks. e) Assessment of test performance through testing previously analyzed specimens, internal blind testing samples or external proficiency testing samples. f) Assessment of problem solving skills. 2. Further review of the laboratory's policy and procedure manual revealed the frequency and how testing personnel competency will be assessed was not included. 3. In interview on December 10, 2019, the Laboratory Director confirmed the laboratory's policy and procedure manual did not include competency assessment for testing personnel. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 3 -- D5609 HISTOPATHOLOGY CFR(s): 493.1273(e)(f) (e) The laboratory must use acceptable terminology of a recognized system of disease nomenclature in reporting results. (f) The laboratory must document all control procedures performed, as specified in this section. This STANDARD is not met as evidenced by: Based on record review and interview with personnel, the laboratory failed to ensure testing personnel documented the stain quality for Hematoxylin and Eosin (H&E) stains. Findings: 1. Review of the laboratory's CMS 209 form (Laboratory Personnel Report) revealed the Laboratory Director serves as the testing personnel. 2. Review of random selection of patients and quality control (QC) records from March 2018 through December 2019 revealed the laboratory did not have documented QC assessment performed for the following dates: Report Date: March 20, 2018 Patient: JS18-08061 Report Date: June 6, 2018 Patient: JS18-19334 Report Date: October 17, 2018 Patient: JS18-37693 Report Date: January 29, 2019 Patient: JS19-03720 Report Date: June 3, 2019 Patient: JS19-23537 Report Date: October 21, 2019 Patient: JS19- 47113 Report Date: November 25, 2019 Patient: JS19-59081 Report Date: December 2, 2019 Patient: JS19-60365 3. In interview on December 10, 2019 at 9:15 am, the Laboratory Director stated he does not document acceptable stain quality for H&E stains. The Laboratory Director further stated if the stain quality is unacceptable he documents and notifies the processing location. The Laboratory Director confirmed for H&E stains acceptable stain quality was not documented. 4. Review of the laboratory's test menu revealed the laboratory performs 3,566 H&E stains annually. D6093 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1445(e)(5) The laboratory director must ensure that the quality control programs are established and maintained to assure the quality of laboratory services provided and to identify failures in quality as they occur. This STANDARD is not met as evidenced by: Based on record review and interview with personnel, the Laboratory Director failed to ensure that a quality control program was established to assure the quality of laboratory testing. Refer to D5609. D6103 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1445(e)(13) The laboratory director must ensure that policies and procedures are established for monitoring individuals who conduct preanalytical, analytical, and postanalytical phases of testing to assure that they are competent and maintain their competency to process specimens, perform test procedures and report test results promptly and proficiently, and whenever necessary, identify needs for remedial training or continuing education to improve skills. This STANDARD is not met as evidenced by: Based on record review and interview with personnel, the Laboratory Director failed -- 2 of 3 -- to ensure complete policies and procedures were established for assessing personnel competency. Refer to D5209. -- 3 of 3 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access

Survey - February 19, 2018

Survey Type: Standard

Survey Event ID: L9YU11

Deficiency Tags: D0000 D5805 D6098 D0000 D5805 D6098

Summary:

Summary Statement of Deficiencies D0000 A Certification Survey was conducted on February 19, 2018 at Delta Pathology Group, LLC, CLIA ID # 19D1056551. The laboratory was found in compliance with 42 CFR 493 Requirements for Laboratories; however, standard level deficiencies were cited. D5805 TEST REPORT CFR(s): 493.1291(c) The test report must indicate the following: (c)(1) For positive patient identification, either the patient's name and identification number, or a unique patient identifier and identification number. (c)(2) The name and address of the laboratory location where the test was performed. (c)(3) The test report date. (c)(4) The test performed. (c)(5) Specimen source, when appropriate. (c)(6) The test result and, if applicable, the units of measurement or interpretation, or both. (c)(7) Any information regarding the condition and disposition of specimens that do not meet the laboratory's criteria for acceptability. This STANDARD is not met as evidenced by: Based on record review and interview with personnel, the laboratory failed to include the address of the laboratory location where testing was performed on Histopathology patient final reports. Findings: 1. Review of random selection of patient test reports revealed the laboratory did not include the physical address of the laboratory where interpretation was performed for the following three (3) patients: Patient 1 Patient 2 Patient 3 2. In interview on February 19, 2018 at 9:19 am, Personnel 1 stated he performs the microscopic examination and interpretation at the laboratory. Personnel 1 further stated he thought the Gretna location's address was sufficient since reports are typed there. Personnel 1 confirmed the physical address of the laboratory where he performs microscopic examination and interpretation was not included on patient final reports. 3. Review of the laboratory's Task 1 and 3 forms revealed the laboratory performs 3,597 Histopathology tests annually. Statement of Deficiencies (X1) Provider/Supplier/CLIA Identification Number (X3) Date Survey Completed Name of Provider or Supplier Street Address, City, State -- 1 of 2 -- D6098 LABORATORY DIRECTOR RESPONSIBILITIES CFR(s): 493.1445(e)(8) The laboratory director must ensure that reports of test results include pertinent information required for interpretation. This STANDARD is not met as evidenced by: Based on record review and interview with personnel, the Laboratory Director failed to ensure the patient test reports included pertinent information required for interpretation. Refer to D5805. -- 2 of 2 --

πŸ”’ Unlock Deficiency Summary

Get full access to the detailed deficiency summary for this facility

One-time payment β€’ Lifetime access